How semaglutide works — the short version
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone your gut naturally releases after eating, which signals your pancreas to produce insulin, slows gastric emptying, and acts on the brain to reduce appetite. Semaglutide mimics this hormone but with a much longer half-life — about 7 days, which allows weekly dosing[1].
The result: lower blood sugar, reduced appetite, significant weight loss, and a cascade of metabolic improvements that show up across your blood panel. The SUSTAIN program (7 trials in type 2 diabetes) and the STEP program (5+ trials in obesity) provide the most comprehensive clinical data on what semaglutide does to blood markers over time[2][3].
Markers that should improve
HbA1c (glycated hemoglobin)
HbA1c reflects your average blood sugar over the preceding 2-3 months. It is the primary efficacy endpoint in diabetes trials and the most reliable measure of glycemic control. The SUSTAIN trials showed semaglutide 1.0 mg reduced HbA1c by 1.5-1.8 percentage points from baseline over 30-56 weeks[2]. The SUSTAIN-7 trial showed semaglutide was superior to dulaglutide at both the 0.5 mg and 1.0 mg doses[4].
Timeline: Meaningful reductions appear within 8-12 weeks. Maximum effect is typically reached by 24-30 weeks. If your HbA1c has not decreased by at least 0.5% after 12-16 weeks, discuss dose adjustment with your prescriber.
What to aim for: For type 2 diabetes, most guidelines target HbA1c below 7.0% (53 mmol/mol). For weight management without diabetes, you would expect HbA1c to remain in the normal range (below 5.7%) and potentially move from the upper end to the lower end of normal.
Fasting glucose and fasting insulin
Fasting glucose decreases on semaglutide through multiple mechanisms: enhanced insulin secretion, reduced glucagon release, and improved insulin sensitivity from weight loss[5]. Fasting insulin often decreases as well — counterintuitively, because as insulin sensitivity improves, the body needs less insulin to maintain normal blood sugar. The HOMA-IR index (calculated from fasting glucose and fasting insulin) consistently improves, indicating reduced insulin resistance.
Lipid panel: triglycerides, LDL, HDL
Semaglutide produces clinically meaningful improvements in the lipid profile. The most consistent effect is on triglycerides, which decreased by 12-21% in SUSTAIN trials[6]. LDL cholesterol shows modest reductions (typically 3-7%), and HDL tends to increase slightly. The STEP trials in obesity showed similar lipid improvements driven by both weight loss and direct GLP-1-mediated effects on hepatic lipid metabolism[3].
If you are tracking ApoB (apolipoprotein B), expect modest reductions in the range of 3-5%, consistent with the LDL changes. ApoB is a more accurate marker of atherogenic particle number than LDL alone and is worth including in your monitoring panel.
Liver enzymes: ALT and AST
This is one of the most striking improvements. Semaglutide significantly reduces liver enzymes, particularly in patients with elevated baseline values or non-alcoholic fatty liver disease (NAFLD). A dedicated phase 2 trial in NASH showed semaglutide 0.4 mg daily resolved steatohepatitis in 59% of patients versus 17% on placebo[7]. ALT reductions of 15-30% from baseline are common in clinical trial data.
The mechanism is straightforward: weight loss reduces hepatic fat, and GLP-1 receptor agonists may have direct anti-inflammatory effects in the liver. If your ALT was mildly elevated before starting semaglutide, expect to see it move toward normal over 3-6 months.
Kidney function
Semaglutide appears to have renal protective effects beyond what weight loss alone would explain. The SUSTAIN-6 cardiovascular outcomes trial showed a 36% reduction in new or worsening nephropathy with semaglutide versus placebo[8]. The ongoing FLOW trial was specifically designed to assess renal outcomes and was stopped early for efficacy, showing semaglutide reduced the risk of kidney disease progression by 24%[9].
In your blood work, this may manifest as stable or slightly improved eGFR and reduced urinary albumin-to-creatinine ratio (UACR). Creatinine should remain stable.
Markers to watch for side effects
Vitamin B12
GLP-1 receptor agonists slow gastric motility, which can impair vitamin B12 absorption. The SUSTAIN trials reported modest but statistically significant decreases in B12 levels over 1-2 years[10]. This is particularly relevant for patients also taking metformin, which independently reduces B12 absorption. Subclinical B12 deficiency can cause fatigue, peripheral neuropathy, and cognitive changes — symptoms that overlap with other conditions and can be missed.
What to do: Check B12 at baseline and at least annually. If B12 falls below 300 pg/mL (many labs use 200 pg/mL as the "low" cutoff, but functional deficiency can occur at higher levels), consider supplementation. Methylcobalamin 1000 mcg sublingual daily is a common approach.
Thyroid function (TSH)
Semaglutide carries a boxed warning about thyroid C-cell tumors based on rodent studies. In these studies, GLP-1 receptor agonists caused dose-dependent increases in thyroid C-cell tumors in rats and mice[11]. Human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells, and no increase in medullary thyroid carcinoma has been observed in clinical trials or post-marketing surveillance to date[12].
Nonetheless, monitoring TSH at baseline and annually is considered prudent. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Lipase and amylase
GLP-1 receptor agonists can cause modest elevations in lipase and amylase — pancreatic enzymes. In most cases, these elevations are subclinical and not associated with pancreatitis[13]. However, semaglutide does carry a warning about pancreatitis risk. If lipase rises above 3x the upper limit of normal, or if the patient develops severe abdominal pain radiating to the back, pancreatitis must be ruled out immediately.
Key distinction: Mild lipase elevation (1-2x ULN) without symptoms is common and typically not actionable. Symptomatic elevation is an emergency.
Heart rate
While not a blood marker, it is worth noting that semaglutide causes a modest increase in resting heart rate — typically 2-4 beats per minute. This has been consistent across trials and appears to be a class effect of GLP-1 receptor agonists[8]. It has not been associated with adverse cardiovascular outcomes — in fact, the SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight/obese patients without diabetes[14].
Expected timeline of blood marker changes
| Marker | 4 weeks | 12 weeks | 24-30 weeks |
|---|---|---|---|
| HbA1c | Early signal | 0.8-1.2% reduction | 1.5-1.8% reduction (max) |
| Fasting glucose | 5-10 mg/dL decrease | 10-20 mg/dL decrease | Stabilized at lower level |
| Triglycerides | Early improvement | 10-15% reduction | 15-21% reduction |
| ALT | Minimal change | 10-15% reduction | 15-30% reduction |
| Body weight | 1-3% loss | 5-8% loss | 10-15% loss |
| B12 | No change | No change | Monitor (may start declining) |
| Lipase | May rise slightly | Stable or mildly elevated | Stable |
Recommended testing schedule
Based on clinical trial monitoring protocols and practical clinical experience, the following schedule covers both efficacy tracking and safety monitoring:
- Baseline (before starting): HbA1c, fasting glucose, fasting insulin, lipid panel (including triglycerides), ALT, AST, creatinine, eGFR, B12, TSH, lipase, CBC. This is your reference point for everything that follows.
- 3 months: HbA1c, fasting glucose, lipid panel, ALT, AST, lipase. This is your first efficacy check — are things moving in the right direction?
- 6 months: Full panel repeat including B12, kidney function, and TSH. By now, you should see the bulk of metabolic improvements.
- 12 months and annually: Full panel. B12 and TSH annually at minimum. Lipid panel and liver enzymes every 6 months if you are tracking specific goals.
When blood markers suggest a problem
Contact your prescriber promptly if your blood work shows any of the following:
- Lipase or amylase exceeds 3x ULN — rule out pancreatitis, especially with symptoms
- B12 drops below 200 pg/mL — supplement immediately and investigate
- eGFR drops sharply — may indicate dehydration from GI side effects (nausea, vomiting, diarrhea) rather than intrinsic kidney damage, but requires assessment
- ALT or AST rises (contrary to the expected improvement) — investigate for other causes of liver injury
- Calcitonin elevation — if included in your panel, elevated calcitonin warrants immediate evaluation for medullary thyroid carcinoma[15]
The bottom line
Semaglutide produces broad, mostly favorable changes across your blood panel. HbA1c, fasting glucose, triglycerides, and liver enzymes should all improve, often substantially. The markers to monitor for potential adverse effects — B12, thyroid function, lipase, and kidney function — are manageable with periodic testing. A baseline panel before starting, a 3-month check, a 6-month full panel, and annual monitoring thereafter gives you a clear picture of both the benefits and any emerging concerns.
Blood work is the most objective way to confirm that semaglutide is doing what clinical trials say it should do for your body. If the numbers align with the trial data, you're on track. If something diverges, you have early signal to investigate.